Influences of intermittent preventive treatment and persistent multiclonal Plasmodium falciparum infections on clinical malaria risk

PLoS ONE

Volumn 5, Issue 10, 2010, Pages

  Liljander, Anne ^a   Chandramohan, Daniel ^b   Kweku, Margaret ^b,c   Olsson, Daniel ^a   Montgomery, Scott M ^a,d,e   Greenwood, Brian ^b   Färnert, Anna ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c UNIVERSITY OF GHANA   (Ghana)

^d ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^e CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE PLUS ARTESUNATE; FANSIDAR; MEROZOITE SURFACE PROTEIN 2; PLACEBO; AMODIAQUINE; ANTIMALARIAL AGENT; MEROZOITE SURFACE PROTEIN 2, PLASMODIUM; PARASITE ANTIGEN; PROTOZOAL PROTEIN; PYRIMETHAMINE; PYRIMETHAMINE PLUS SULFADOXINE; SULFADOXINE; SULFADOXINE-PYRIMETHAMINE;

ANEMIA; ARTICLE; BLOOD SAMPLING; CHILD; CLINICAL TRIAL; CLONE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; FOLLOW UP; GENE; GENETIC VARIABILITY; GENOTYPE; GHANA; HUMAN; INFANT; INFECTION RISK; MAJOR CLINICAL STUDY; MALARIA CONTROL; MALARIA FALCIPARUM; MEROZOITE SURFACE PROTEIN 2 GENE; MICROSCOPY; MOLECULAR TYPING; MORBIDITY; PRESCHOOL CHILD; PROTECTION; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK REDUCTION; TREATMENT DURATION; CROSS-SECTIONAL STUDY; DRUG COMBINATION; GENETICS; RISK FACTOR;

ARTESUNATE; PLASMODIUM FALCIPARUM;

AMODIAQUINE; ANTIGENS, PROTOZOAN; ANTIMALARIALS; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; DRUG COMBINATIONS; GHANA; HUMANS; INFANT; MALARIA, FALCIPARUM; PLACEBOS; PROTOZOAN PROTEINS; PYRIMETHAMINE; RISK FACTORS; SULFADOXINE;

EID: 78149430451     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013649     Document Type: Article

References (30)

1. WHO World Malaria Report. Available: http://malaria.who.int/wmr2008/malaria2008.pdf. Accessed 13 December 2009.
2. Gies S, Coulibaly SO, Ouattara FT, D'Alessandro U (2009) Individual efficacy of intermittent preventive treatment with sulfadoxine-pyrimethamine in primiand secundigravidae in rural Burkina Faso: impact on parasitaemia, anaemia and birth weight. Trop Med Int Health 14: 174-182.
3. Aponte JJ, Schellenberg D, Egan A, Breckenridge A, Carneiro I, et al. (2009) Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials. Lancet 374: 1533-1542.
4. WHO Report of the Technical Consultation on Intermittent Preventive Treatment in Infants (IPTi), Technical Expert Group on Preventive Chemotherapy, 23-24 April 2009 - WHO\HQ, Geneva, Switzerland. Document available at: http://www.who.int/malaria/publications/atoz/tegconsultiptiapr2009report .pdf.
5. Cisse B, Sokhna C, Boulanger D, Milet J, Bael H, et al. (2006) Seasonal intermittent preventive treatment with artesunate and sulfadoxine-pyrimethamine for prevention of malaria in Senegalese children: a randomised, placebocontrolled, double-blind trial. Lancet 367: 659-667.
6. Dicko A, Sagara I, Sissoko MS, Guindo O, Diallo AI, et al. (2008) Impact of intermittent preventive treatment with sulphadoxine-pyrimethamine targeting the transmission season on the incidence of clinical malaria in children in Mali. Malar J 7: 123.
7. Greenwood BM, David PH, Otoo-Forbes LN, Allen SJ, Alonso PL, et al. (1995) Mortality and morbidity from malaria after stopping malaria chemoprophylaxis. Trans R Soc Trop Med Hyg 89: 629-633.
8. Menendez C, Kahigwa E, Hirt R, Vounatsou P, Aponte JJ, et al. (1997) Randomised placebo-controlled trial of iron supplementation and malaria chemoprophylaxis for prevention of severe anaemia and malaria in Tanzanian infants. Lancet 350: 844-850.
9. Chandramohan D, Owusu-Agyei S, Carneiro I, Awine T, Amponsa-Achiano K, et al. (2005) Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana. BMJ 331: 727-733.
10. Kweku M, Liu D, Adjuik M, Binka F, Seidu M, et al. (2008) Seasonal intermittent preventive treatment for the prevention of anaemia and malaria in Ghanaian children: a randomized, placebo controlled trial. PLoS One 3: e4000.
11. Mockenhaupt FP, Reither K, Zanger P, Roepcke F, Danquah I, et al. (2007) Intermittent preventive treatment in infants as a means of malaria control: a randomized, double-blind, placebo-controlled trial in northern Ghana. Antimicrob Agents Chemother 51: 3273-3281.
12. Ofosu-Okyere A, Mackinnon MJ, Sowa MP, Koram KA, Nkrumah F, et al. (2001) Novel Plasmodium falciparum clones and rising clone multiplicities are associated with the increase in malaria morbidity in Ghanaian children during the transition into the high transmission season. Parasitology 123: 113-123.
13. Bendixen M, Msangeni HA, Pedersen BV, Shayo D, Bodker R (2001) Diversity of Plasmodium falciparum populations and complexity of infections in relation to transmission intensity and host age: a study from the Usambara Mountains, Tanzania. Trans R Soc Trop Med Hyg 95: 143-148.
14. Branch OH, Takala S, Kariuki S, Nahlen BL, Kolczak M, et al. (2001) Plasmodium falciparum genotypes, low complexity of infection, and resistance to subsequent malaria in participants in the Asembo Bay Cohort Project. Infect Immun 69: 7783-7792.
15. Konate L, Zwetyenga J, Rogier C, Bischoff E, Fontenille D, et al. (1999) Variation of Plasmodium falciparum msp1 block 2 and msp2 allele prevalence and of infection complexity in two neighbouring Senegalese villages with different transmission conditions. Trans R Soc Trop Med Hyg 93(Suppl 1): 21-28.
16. al-Yaman F, Genton B, Reeder JC, Anders RF, Smith T, et al. (1997) Reduced risk of clinical malaria in children infected with multiple clones of Plasmodium falciparum in a highly endemic area: a prospective community study. Trans R Soc Trop Med Hyg 91: 602-605.
17. Bereczky S, Liljander A, Rooth I, Faraja L, Granath F, et al. (2007) Multiclonal asymptomatic Plasmodium falciparum infections predict a reduced risk of malaria disease in a Tanzanian population. Microbes Infect 9: 103-110.
18. Farnert A, Williams TN, Mwangi TW, Ehlin A, Fegan G, et al. (2009) Transmission-dependent tolerance to multiclonal Plasmodium falciparum infection. J Infect Dis 200: 1166-1175.
19. Henning L, Schellenberg D, Smith T, Henning D, Alonso P, et al. (2004) A prospective study of Plasmodium falciparum multiplicity of infection and morbidity in Tanzanian children. Trans R Soc Trop Med Hyg 98: 687-694.
20. Mayor A, Saute F, Aponte JJ, Almeda J, Gomez-Olive FX, et al. (2003) Plasmodium falciparum multiple infections in Mozambique, its relation to other malariological indices and to prospective risk of malaria morbidity. Trop Med Int Health 8: 3-11.
21. Liljander A, Wiklund L, Falk N, Kweku M, Martensson A, et al. (2009) Optimization and validation of multi-coloured capillary electrophoresis for genotyping of Plasmodium falciparum merozoite surface proteins (msp1 and 2). Malar J 8: 78.
22. Beck HP, Felger I, Huber W, Steiger S, Smith T, et al. (1997) Analysis of multiple Plasmodium falciparum infections in Tanzanian children during the phase III trial of the malaria vaccine SPf66. J Infect Dis 175: 921-926.
23. Roper C, Richardson W, Elhassan IM, Giha H, Hviid L, et al. (1998) Seasonal changes in the Plasmodium falciparum population in individuals and their relationship to clinical malaria: a longitudinal study in a Sudanese village. Parasitology 116(Pt 6): 501-510.
24. Farnert A, Rooth I, Svensson, Snounou G, Bjorkman A (1999) Complexity of Plasmodium falciparum infections is consistent over time and protects against clinical disease in Tanzanian children. J Infect Dis 179: 989-995.
25. Muller DA, Charlwood JD, Felger I, Ferreira C, do Rosario V, et al. (2001) Prospective risk of morbidity in relation to multiplicity of infection with Plasmodium falciparum in Sao Tome. Acta Trop 78: 155-162.
26. Fruh K, Doumbo O, Muller HM, Koita O, McBride J, et al. (1991) Human antibody response to the major merozoite surface antigen of Plasmodium falciparum is strain specific and short-lived. Infect Immun 59: 1319-1324.
27. Otoo LN, Snow RW, Menon A, Byass P, Greenwood BM (1988) Immunity to malaria in young Gambian children after a two-year period of chemoprophylaxis. Trans R Soc Trop Med Hyg 82: 59-65.
28. Schreiber N, Kobbe R, Adjei S, Adjei O, Klinkert MQ, et al. (2007) Immune responses after single-dose sulphadoxine-pyrimethamine indicate underestimation of protective efficacy of intermittent preventive treatment in infants. Trop Med Int Health 12: 1157-1163.
29. Babiker HA, Abdel-Muhsin AM, Ranford-Cartwright LC, Satti G, Walliker D (1998) Characteristics of Plasmodium falciparum parasites that survive the lengthy dry season in eastern Sudan where malaria transmission is markedly seasonal. Am J Trop Med Hyg 59: 582-590.
30. Nassir E, Abdel-Muhsin AM, Suliaman S, Kenyon F, Kheir A, et al. (2005) Impact of genetic complexity on longevity and gametocytogenesis of Plasmodium falciparum during the dry and transmission-free season of eastern Sudan. Int J Parasitol 35: 49-55.